GLUE · NASDAQ
Monte Rosa Therapeutics (GLUE) Stock Price & Fundamentals
Monte Rosa Therapeutics (GLUE) closed at $765.65 on Oct 9, 2026, down 0.22% from the previous close of $767.34.
Share price, past year
1Y +13.08%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $765.65 |
| Sep 30, 2026 | $760.90 |
| Aug 31, 2026 | $819.35 |
| Jul 31, 2026 | $749.18 |
| Jun 30, 2026 | $732.21 |
| May 29, 2026 | $749.77 |
| Apr 30, 2026 | $749.41 |
| Mar 31, 2026 | $775.68 |
| Feb 27, 2026 | $725.80 |
| Jan 30, 2026 | $727.50 |
| Dec 31, 2025 | $731.04 |
| Nov 28, 2025 | $726.54 |
| Oct 31, 2025 | $731.33 |
Key statistics
- Market cap
- $65.25B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $28.73M
- Net income (TTM)
- −$161.09M
- Shares outstanding
- 85.2M
- Dividend yield
- —
- 52-week range
- $675.16 – $825.48
Monte Rosa Therapeutics's market cap is $65.25B, based on a share price of $765.65 and 85.2M shares outstanding as of Jun 30, 2026.
Financials
Monte Rosa Therapeutics reported revenue of $123.67M for fiscal 2025, up 63.54% from fiscal 2024.
Monte Rosa Therapeutics reported a net loss of $38.60M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $123.67M | +63.5% | −$38.60M | −31.2% | — | −$27.50M |
| FY2024ended Dec 31, 2024 | $75.62M | — | −$72.70M | −96.1% | — | $38.01M |
| FY2023ended Dec 31, 2023 | $0.00 | — | −$135.35M | — | — | −$62.84M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $8.97M | −$43.40M | — |
| Q1 FY2026ended Mar 31, 2026 | $4.21M | −$44.50M | — |
| Q4 FY2025ended Dec 31, 2025 | $2.78M | −$46.11M | — |
| Q3 FY2025ended Sep 30, 2025 | $12.77M | −$27.08M | — |
| Q2 FY2025ended Jun 30, 2025 | $23.19M | −$12.30M | — |
| Q1 FY2025ended Mar 31, 2025 | $84.93M | $46.89M | — |
| Q4 FY2024ended Dec 31, 2024 | $60.65M | $13.44M | — |
| Q3 FY2024ended Sep 30, 2024 | $9.22M | −$23.86M | — |
Company profile
- Name
- Monte Rosa Therapeutics, Inc.
- Ticker
- GLUE
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 321 Harrison Avenue, Suite 900, Boston, MA 02118
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001826457
Recent SEC filings
- Oct 1, 2026
- Sep 8, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jun 11, 2026
- May 7, 2026
- May 7, 2026
- Mar 17, 2026
Frequently asked questions
What is Monte Rosa Therapeutics's stock price?
Monte Rosa Therapeutics (GLUE) closed at $765.65 on Oct 9, 2026, down 0.22% from the previous close of $767.34.
What is Monte Rosa Therapeutics's market cap?
Monte Rosa Therapeutics's market cap is $65.25B, based on a share price of $765.65 and 85.2M shares outstanding as of Jun 30, 2026.
How much revenue does Monte Rosa Therapeutics make?
Monte Rosa Therapeutics reported revenue of $123.67M for fiscal 2025, up 63.54% from fiscal 2024.
Does Monte Rosa Therapeutics pay a dividend?
Monte Rosa Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Monte Rosa Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures